Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
89.65
+2.32 (2.66%)
At close: Dec 5, 2025, 4:00 PM EST
89.00
-0.65 (-0.73%)
After-hours: Dec 5, 2025, 6:37 PM EST
Protagonist Therapeutics Revenue
Protagonist Therapeutics had revenue of $4.71M in the quarter ending September 30, 2025, with 0.79% growth. This brings the company's revenue in the last twelve months to $209.22M, down -35.39% year-over-year. In the year 2024, Protagonist Therapeutics had annual revenue of $434.43M with 624.06% growth.
Revenue (ttm)
$209.22M
Revenue Growth
-35.39%
P/S Ratio
27.06
Revenue / Employee
$1,660,452
Employees
126
Market Cap
5.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
| Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
| Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
| Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
| Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PTGX News
- 4 hours ago - Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - Business Wire
- 4 weeks ago - Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 4 weeks ago - Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Accesswire
- 7 weeks ago - Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make - Seeking Alpha
- 2 months ago - Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - The Motley Fool
- 2 months ago - Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Benzinga
- 2 months ago - Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports - Reuters
- 2 months ago - Johnson & Johnson in Talks to Buy Protagonist Therapeutics - WSJ